1973 With D. Tripodi, J. Struck, C. M. Zmijewski, and W. Pollack. Hemolytic anemia associated with Rhnull but not with Bombay blood: A hypothesis based on differing antigenic structures. Vox Sang. 24:417.

1974 Differences between Bombay and Rhnull phenotypes. Vox Sang. 26:272.

1975 With R. E. Rosenfield and C. Heller. Quantitative Rh typing of rGr G with observations on the nature of G (Rh 12) and anti-G. Vox Sang. 28:293.

ABO, MN, P and Rh revisted. The illegitimacy of malignant tissue. In the XIV Congress of the International Society of Blood Transfusion, Helsinki, Finland.

1976 Biological and clinical significance of differences between RBC membrane (Rh) and non-membrane (ABH, MN, P) antigenic sites. Illegitimate ABO, M-N(T), P(Tja) antigens in malignancy. Rev. Franc. Transf. et Immunohemat. 19:1.

1979 With H. Kitamura, P. J. Cheng, R. A. Egeli, Y. P. Liu, R. A. Good, and N. K. Day. Forssman-like antibody levels in sera of patients with lung cancer. Cancer Res. 39:2909.

With W. W. Young and S. I. Hakomori. Characterization of anti-Forssman (anti-FS) antibodies in human sera—their specificity and possible changes in patients with cancer . J. Immunol. 123:92.

1982 With R. Kannagi, K. Watanabe, and S. I. Hakomori. Recent studies of glycolipid and glycoprotein profiles and characterization of the major glycolipid antigen in gastric cancer of a patient of blood group genotype pp (Tja neg.) first studied in 1951. Cancer Res. 42:5249.

1984 The discovery of Rh hemolytic disease. Vox Sang. 47:187.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement